



Now Available in the U.S.

Alfaxan[®]
(alfaxalone 10 mg/mL)

Intravenous Injectable Anesthetic

**Repeatable.
Reliable.
Relax.**



Jurox

FEATURES:

Contains Alfaxalone, a new and unique molecule approved for anesthesia in both cats and dogs

A low-dose volume, clear, colorless, aqueous, iso-osmotic solution with neutral pH

Extensive global research program including tolerance and compatibility studies published in peer-reviewed journals

Available in Europe, Asia and Australia, with more than 10 years clinical experience

FUNCTIONS:

Smooth onset of anesthesia with no cumulative effects and rapid clearance from the circulation

No pain on injection and no tissue irritation

Proven clinical efficacy; compatibility with all common pre-anesthetic agents and tolerance up to 10 times recommended dose

Induction and maintenance of anesthesia in more than 6 million patients

BENEFITS:

Stress-free induction, suitable for anesthetic maintenance and ensures rapid return to normal physiology and behavior

Reliable, stress-free transition to maintenance

Alfaxan's wide safety margin means it can be confidently introduced into current anesthetic protocols

Confidence and peace of mind to adopt a product proven repeatable and reliable in practices across the globe

INDICATIONS: Alfaxan[®] is indicated for the induction and maintenance of anesthesia and for induction of anesthesia followed by maintenance with an inhalant anesthetic, in cats and dogs.

Important Alfaxan[®] Risk Information: Warnings, Precautions and Contraindications: When using alfaxalone, patients should be continuously monitored, and facilities for the maintenance of a patent airway, artificial ventilation, and oxygen supplementation must be immediately available. Alfaxan[®] does not contain an antimicrobial preservative. Do not use if contamination is suspected. Strict aseptic techniques must be maintained because the vehicle is capable of supporting the rapid growth of microorganisms. Careful monitoring of the patient is necessary due to the possibility of rapid arousal. Alfaxan[®] is contraindicated in cats and dogs with a known sensitivity to alfaxalone or its components, or when general anesthesia and/or sedation are contraindicated. Adverse

Reactions: The most common side effects of alfaxalone include respiratory and cardiovascular derangements, such as apnea, hypotension and hypertension. Appropriate analgesia should be provided for painful procedures.

Alfaxan[®] is a registered trademark of Jurox Pty. Limited, Australia.

**Sound
Byte**

Alfaxan Facts:

1. Developed by Jurox, an Australian, family-owned animal health company
2. Ready-to-use aqueous formulation has been on the market since 2001
3. 'Veterinary industry only' focused company
4. Leading choice induction anesthetic in Australia: 52.5% market share in dogs, 74% in cats¹
5. Alfaxan website – alfaxan.com
6. Anesthesia Community to support Alfaxan; online technical community: www.alfaxan.com/community
7. Customer service number: 844-ALFAXAN

¹ Independent Anaesthesia Market Research by Baron Strategic Services, Oct. 2011



ALFAXAN Induction Dose Guidelines: CATS

Preanesthetic	Average ALFAXAN induction dose (and range) in mg/kg	Number of cats
No preanesthetic	4.0 (2.2-9.7)	33
Opioid + phenothiazine	3.2 (1.1-10.8)	96
Benzodiazepine + phenothiazine	3.6 (1.5-7.1)	23
Benzodiazepine + opioid + phenothiazine	2.3 (1.2-5.0)	26
Alpha ₂ -adrenergic agonist with/without phenothiazine	3.6 (1.1-5.0)	15
Alpha ₂ -adrenergic agonist + phenothiazine with/without benzodiazepine or opioid	2.9 (1.0-3.9)	11

ALFAXAN Induction Dose Guidelines: DOGS

Preanesthetic	Average ALFAXAN induction dose (and range) in mg/kg	Number of dogs
No preanesthetic	2.2 (1.5-4.5)	17
Benzodiazepine + opioid + acepromazine	1.7 (0.9-3.5)	39
Opioid + acepromazine	1.6 (0.6-3.5)	80
Alpha ₂ -agonist	1.1 (0.21-2.00)	9

ALFAXAN Maintenance Dose Guidelines: DOGS

	Preanesthetized dogs	Unpreanesthetized dogs
Maintenance anesthesia doses	1.2-1.4 mg/kg	1.5-2.2 mg/kg
Mean duration of anesthesia	6-8 minutes	6-8 minutes

Sound Byte

CHECK-OFF & ECHO NOTES

Qualify: Identify if an Alfaxan® representative has been in recently:

Doctor, have you been introduced to Alfaxan® the new IV injectable anesthetic for use in cats and dogs from Jurox?

If **YES**, confirm and discuss benefits

If **NO**, engage/detail the customer as the primary contact

Confidence

I believe Alfaxan provides the safety and efficacy you desire for the induction and maintenance of anesthesia.

Invitation (neutral)

Let me describe the benefits of Alfaxan...

It's the Customer's Decision

...so you can determine if it is right for your practice.

About Us

Jurox is an established family-owned veterinary pharmaceutical company that manufactures and markets in excess of 120 proprietary animal health products in over 20 countries. With global headquarters in the Hunter Valley Australia, Jurox maintains commercial operations in New Zealand, United Kingdom and has recently established its U.S. headquarters in Kansas City, Missouri.

Jurox invests ~15% of sales in research and development, much of which is carried out on the group's own research stations. The Company is GMP certified under MRA, US FDA inspected and NATA recognized for compliance with the OECD Principles of Good Laboratory Practice and ISO17025 Laboratory Accredited.

Jurox's mission is to deliver uncompromised quality driven by innovation, adding value for customers willing to work with a long-term partner committed to supporting their business' needs. Jurox aims to provide veterinarians, pet owners and livestock producers with innovative and practical solutions to improve the well-being and sustainability of animal health.

